Consistent with our data, KPT-330 has been shown to inhibit SDF1-mediated signalling, preventing the migration of CLL cells34, and to restrict tumour spreading and the metastasis of prostate cancer cells by decreasing the secretion of metalloproteinases and urokinase35. Here, CXCL12 is linked to neoplasm.